BrightGene Bio-Medical Technology Co., Ltd.

Equities

688166

CNE100003PR1

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-06-11 pm EDT 5-day change 1st Jan Change
36.15 CNY +1.83% Intraday chart for BrightGene Bio-Medical Technology Co., Ltd. +1.69% +3.29%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
China Shares Rise as Property Market Gets Relief; BrightGene Jumps 7% MT
BrightGene to Sell 500 Million Yuan Shares to Actual Controller; Shares Up 3% MT
BrightGene Bio-Medical Technology Co., Ltd. announced that it expects to receive CNY 499.999987 million in funding CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on BrightGene Bio-Medical Technology Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024. CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BrightGene Bio-Medical Technology Co., Ltd. announces an Equity Buyback for CNY 20 million worth of its shares. CI
BrightGene Bio-Medical Technology Co., Ltd. authorizes a Buyback Plan. CI
Oralead Pharma announced that it has received funding from HighLight Capital, Shenzhen Qianhai BangQin Investment Co., Ltd., BrightGene Bio-Medical Technology Co., Ltd., Shenyang Borui Pharmaceutical Co., Ltd. CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Chinese Regulator Issues Warning Against BrightGene Bio-Medical Chairman Over Weight Loss Claims MT
Kanghui Pharma Denies Speculations of Unit’s Involvement in Production of Weight-Loss Drugs MT
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
BrightGene Bio-Medical Technology's Unit Gets Hospital's Approval for Diabetes Drug Trial MT
Chinese Drug Regulator Certifies Two Drugs of BrightGene's Unit MT
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
BrightGene Bio-Medical to Hike Investment in API Production Project to 500 Million Yuan MT
Xinchuang Biomedical Technology Subsidiary Gets Nod to Hold Anti-Diabetes Drug Trial MT
BrightGene Bio-Medical Technology Co., Ltd. announced that it has received CNY 226.613082 million in funding from Horizon Asset Management Co. Ltd., Shanghai Leitu Asset Management Co., Ltd. and other investors CI
BrightGene Bio-Medical Technology Unit Gets Regulatory Approval For Anti-Inflammatory Drug Ingredient MT
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
BrightGene Bio-Medical Technology Co., Ltd.(SHSE:688166) dropped from Shanghai Stock Exchange Health Care Sector Index CI
Suzhou Hongbo Venture Capital Partnership agreed to acquire 2.42% stake in Caike Biotechnology Co., Ltd. from BrightGene Bio-Medical Technology Co., Ltd. for CNY 20 million. CI
Chart BrightGene Bio-Medical Technology Co., Ltd.
More charts
BrightGene Bio-Medical Technology Co Ltd is a China-based company mainly engaged in the research, development and production of generic drugs and original new drugs. The Company's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The Company's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The Company mainly conducts its businesses in domestic and overseas markets.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688166 Stock
  4. News BrightGene Bio-Medical Technology Co., Ltd.
  5. China Shares Rise as Property Market Gets Relief; BrightGene Jumps 7%